European Union: EU Court To Clarify Medical Device / Drug Borderline And The Status Of MEDDEV Documents

Last Updated: 10 October 2011
Article by Erik Vollebregt

Important developments for the medical devices and medicinal products industry: clarification of EU law about the borderline between these groups of products is currently in the making at the European Court of Justice. The German Oberlandesgericht Frankfurt am Main referred a reference for preliminary ruling to the European Court of Justice, which was lodged there on 20 June 2011 under number C-308/11. The case concerns the borderline between medicinal products in the meaning of applicable EU law and medical devices, and it turns on the ever problematic demarcation question: "What does pharmacological action mean?". Although the particulars of the dispute are as yet difficult to ascertain and I was not able to find any in public sources, we do know the three questions that were referred to the European Court in order to obtain a highest instance interpretation of concepts of EU law:

  1. For the purpose of defining the term 'pharmacological action' in Article 1(2)(b) of Directive 2001/83/EC, as amended by Directive 2004/27/EC, can recourse be had to the document compiled under the auspices of the European Commission to provide guidance in distinguishing between medicinal products and medical devices (the 'Medical Devices: Guidance document'), which states that there must be an interaction between the molecules of the substance in question and a cellular constituent, usually referred to as a receptor, which either results in a direct response or blocks the response of another agent?
  2. If the first question is answered in the affirmative: does the term 'pharmacological action' require that there should be an interaction between the molecules of the substance in question and cellular constituents of the user, or is it sufficient if there is an interaction between the substance in question and a cellular constituent which does not form part of the human body?
  3. In the event that the first question is answered in the negative or that neither of the two definitions proposed in the second question is appropriate: which alternative definition should be used instead?

It will be a while before we will first see the opinion of the Advocate General in this matter and subsequently the Court's judgement. I expect about nine months for the opinion of the AG and then another three to six months for the Court's judgment.

Borderlines and pharmacological action

Let's take a step back in the mean time and look at borderlines again. As I have argued on this year's DIA Euromeeting, the use of the term borderLINE is not helpful from a scientific perspective, because borderline questions are in the end scientific questions, and no so much legal questions and for that reason it would be more appropriate to speak about a border area, in which the edges of two or more regulatory regimes (like in this case medicinal products and medical devices) overlap. Judges, as I have shown in that presentation, are not at all well-equipped to decide scientific questions.

What do we know already about how the European Court interprets 'pharmacological action' and what factual support it requires for its interpretation? We know that the legal criterion is that a product, for it to constitute a medicinal product by function, must "significantly affect the metabolism and thus modify the way in which it functions" (see BIOS Naturprodukte, point 21). The question then is: "Does 'significantly affect the metabolism and thus modify the way in which it functions' require that there should be an interaction between the molecules of the substance in question and cellular constituents of the user, or is it sufficient if there is an interaction between the substance in question and a cellular constituent which does not form part of the human body?"

To ask this question is to answer it: that depends on whether the interaction between the substance and the cellular constituent that does not form part of the body is still capable of restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action. It is difficult to answer this question without any knowledge of the product concerned, but excluding interactions between substance and cellular constituent removed from the body could have consequences for the Advanced Therapy Medicinal Products Regulation. This regulation relies on Directive 2001/83/EC for its core definition of medicinal product (see article 2 (a)) and the core criterion of 'substantial manipulation' (article 2 (c)) presumes that often procedures will be applied to cellular constituents that do not form part of the body.

My guess therefore is that the European Court will bounce this question right back in the way I just did: it will repeat its case law and then leave it to the national court to decide on the facts if the interaction between the substance and the cellular constituent that does not form part of the body is still capable of restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action.

Furthermore, the first question of the preliminary reference misrepresents the MEDDEV in that it suggests that the MEDDEV requires "an interaction between the molecules of the substance in question and a cellular constituent usually referred to as a receptor, which either results in a direct response, or which blocks the response to another agent.", because the question is phrased that the MEDDEV "states that there must be an interaction" (bold and underlining added). In the text of the MEDDEV (see p. 6) the element describing 'interaction' is however immediately followed by this statement:

"Although not a completely reliable criterion, the presence of a dose-response correlation is indicative of a pharmacological effect."

Wait a second, all my lawyer alarms are going off now. Not a completely reliable criterion? Correlation? Indicative? There is the wiggle room in science that the European Court will use as described above. The fact that the German judge posed the question as a positive "must" while science in these cases only speaks about "not completely reliable criterion", "correlation" and "indicative" underlines my thesis that judges are really not that well equipped to answer scientific questions, especially when there is correlation involved, which they all too often mistake for causality, as a Dutch judge recently did in a case involving a dispute about the outcome of a statistical analysis of clinical trial data. So, again, knowing the European Court a bit, it will rephrase the first question to be able to give a useful answer, state that the causal link implied does not exist, and then repeat the criteria from its case law set out above, to finally hand it down again to the Frankfurt am main Oberlandesgericht to apply the criterion that did not change at all to the actual facts of the case, which it just should have done in the first place like the Hecht Pharma case prescribes (points 38-45).

This case does show however that there is demand for a supra-national EU capability to make borderline product calls between the different regulated products regimes, which sources close the Recast drafting process tell me is likely to make it politically. If that is instated cases like this could actually be decided on an EU level.

Status of MEDDEVS

Some further remarks about this case: the status of MEDDEVs - can one have recourse to these documents in legal proceedings? The first preliminary question obviously refers to MEDDEV 2.1/3 on Borderline products, drug-delivery products and medical devices incorporating,as integral part, an ancillary medicinal substance or an ancillary human blood derivative, last updated in December 2009. In addition there is a Manual on borderline and classification in the Community Regulatory framework for medical devices containing guidance on a number of specific borderline cases, last updated in August this year. In response to a Parliamentary Question about MEDDEV 2.1/3 the Commission answered in 2008:

"Moreover, in order to ensure a uniform approach within the Community, the Commission services have drafted a Manual that represents the agreed position of the Medical Device Expert Group 'Borderline and Classification' on specific borderline products or categories of products. This Manual will be regularly updated in the light of the discussions of this group. Once endorsed by the Medical Device Expert Group 'Borderline and Classification' the Manual will be published on the Commission's website.

In order to update the MEDDEV guidance 2.1/3, the Commission services have undertaken a broad written consultation of stakeholders through the involvement of the abovementioned expert group, which includes experts from Member States' competent authorities, the relevant Commission services, the European Medicines Agency and industry trade associations. These stakeholders were asked to send their written contributions on the draft revised guidance by the end of January 2008.

Due to the participation of the aforementioned interested parties and of experts from competent authorities, it is anticipated that this guidance will be followed within the Member States and, therefore, will ensure uniform application of the directives."

So, it is clear that the MEDDEV and the Manual were both drafted with participation of the authorities of the Member States and that they are supposed to adhere to them because they are stakeholders in it. Does that impose an obligation for member states to act according to the MEDDEV? That will really first of all depend on national law governing policy documents because as we have seen: the EU has no competence under the current rules to decide in this matters. That is done by national authorities and judges.

The status of the MEDDEV is clearer to me than the status of the Manual although they address the exact same thing. The MEDDEV is a document drafted and released by the Commission itself after consultation with interested parties, as the Commission page on MEDDEVs explains. Such documents are not binding on the Commission but may serve to help the Commission meet its obligation to give reasoned decisions, as has been established in competition law cases (see for example Corsica Ferries, point 66). The documents can however never overrule or pre-empt the European Court's or national courts' interpretation of the EU statutes concerned, as these documents make quite clear themselves. MEDDEVs therefore only bind the Commission and then only insofar as the Commission uses them to give reasons for its decisions. One earlier case that was filed as a direct action claiming that the Court of First Instance should order the Commission to make a notified body act as set out in a MEDDEV failed quite spectacularly (sorry, the actual judgment in this case is only available in French).

The Manual is much more interesting, because the group behind that (the Medical Device Expert Group 'Borderline and Classification') consists of industry, trade associations and notified bodies. The Commission merely publishes the manual on its website if al of these parties agree. Even if this case clarifies the status of MEDDEV, it will  not clarify the status of the Manual, which deals with the exact same questions and is also a reflection of positions of representatives of Competent Authorities, Notified Bodies, industry and other interested parties in the medical devices sector.

However, my guess here is that the European Court will say that it is for the German court to decide under German law to what extent it and German authorities are bound by MEDDEVs and Manuals they helped write, provided of course that they can never act contrary to EU law in the application of that law because Germany has the duty to ensure effective application of EU law on its territory.


An interesting case, although there is not much known about it yet until the AG opinion comes out. That should contain a good description of the facts underlying this case. In the mean time I could not help myself and had to write this speculative post. If any reader of this blog has more information about this case, I would be much obliged! Discussion about the outcome of the case is more than welcome too.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.